Call 215.510.2245

203 N. 3rd St., #6, Philadelphia, PA 19106
Phone: 215.510.2245
Contact Us

Dangerous Drugs

J&J and Bayer Aim to Expand XARELTO Indication Despite Current Health Risks

Johnson & Johnson and Bayer’s Xarelto is already in the lead of the new generation of anticoagulants. Recently, the drugmakers made known that they are looking to expand that market lead with new clinical trials aimed at widening the drug’s label.

Xarelto has been the focus of widespread attention […]

Read More

Increased Focus on Xarelto Injuries

Xarelto (rivaroxaban) is one of the newest blood thinners on the market and is manufactured by Bayer and marketed by Johnson & Johnson’s subsidiary, Janssen Pharmaceuticals, in the United States. The drug was approved in 2011. […]

Read More

The Game Is On – Menopausal Women a Huge Target for Antidepressant Medications

Menopausal women are a major target for drug companies and their respective antidepressant medications.  In June 2013, the FDA has approved Brisdelle for hot flashes.  The FDA approved the drug against the advisory panel’s recommendation.  Brisdelle, manufactured by Noven Therapeutics, is an antidepressant – it is Paxil (FDA approved in 1992) with another name and a different color. […]

Read More

Iclusig Leukemia Drug: Reports of Deaths and Serious Injury

Reports of over a dozen deaths and serious injury to others from “fast track approval” drug Iclusig has prompted Ariad pharmaceutical to suspend all sales, marketing and clinical trials of the drug immediately. […]

Read More

Is Testosterone Gel Men’s Fountain of Youth or Just Another Cause for a Heart Attack?

A November 2013 study published in the Journal of the American Medical Association has linked the use of testosterone gels to cardiovascular injuries such as heart attacks and strokes. According to the study, veterans with a history of heart disease had a much higher risk of death, heart attack and strong after testosterone gel treatment.[…]

Read More

Johnson & Johnson Still Hiding the Ball – Will It Ever Learn?

In the recent Risperdal litigation, there is strong evidence that Johnson & Johnson (J&J) manipulated data in various studies to hide the true risk of gynecomastia (breast growth) in children.[…]

Read More

FDA Looking At Pradaxa (Dabigatran) With A Closer Eye

Since the approval of dabigatran (Pradaxa, Boehringer Ingelheim) in Europe in 2008 and in the US in 2010 there have been serious concerns about the drug’s safety.  The FDA has just announced that it plans to perform a new large assessment of Pradaxa compared to warfarin.[…]

Read More

Free Case Review